Fig 1: Febuxostat dose-dependently alleviated the CP-induced changes in the testicular tissue (A) NLRP3 inflammasome and (B) gasdermin D. Data are presented as mean ± standard deviation (SD) (number of animals = ten per group) and statistically analyzed using one-way ANOVA, confirmed by Tukey’s multiple comparison test. p-value < 0.05 was considered significant. Abbreviations: CP, cyclophosphamide; FBX5: febuxostat 5 mg/kg/day; FBX10: febuxostat 10 mg/kg/day; FBX15: febuxostat 15 mg/kg/day; NLRP3, nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3.
Fig 2: The experimental procedures and the measured parameters of the study. Abbreviations: Akt, protein kinase B; β-HSD, beta hydroxysteroid dehydrogenase; CP, cyclophosphamide; FSH, follicle-stimulating hormone; HMGB1, high mobility group box 1; LH, luteinizing hormone; mTOR, mammalian target of rapamycin; NLRP3, NOD-like receptor family pyrin domain-containing 3; PI3K, phosphatidylinositol 3 kinase; RAGE, receptors for advanced glycation end products; SIRT1, silent information regulator 1; TLR4, toll-like receptor 4.
Fig 3: The mechanisms by which febuxostat can prevent testicular dysfunction in cyclophosphamide-induced testicular toxicity in rats (This artwork was created using Reactome icon library and Smart Art Servier items). Abbreviations: HMGB1, high mobility group box 1; NLRP3, NOD-like receptor family pyrin domain-containing 3; RAGE, receptors for advanced glycation end products; ROS, reactive oxygen species; SIRT1, silent information regulator 1; TLR4, toll-like receptor 4. The red lines denote inhibition and the green lines denote activation.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for Rat NLRP3/NALP3 ELISA Kit (Colorimetric)
Available conjugates: Sizes Available: 1 Kit